OBIO
Orchestra BioMed Holdings, Inc.NASDAQHealthcare$4.27-1.61%ClosedMarket Cap: $249.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.59
P/S
7.46
EV/EBITDA
-4.83
DCF Value
$-0.01
FCF Yield
-19.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-154.7%
Net Margin
-157.4%
ROE
-169.6%
ROA
-45.9%
ROIC
-52.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $30.9M | 99.8% | $6.8M | $6.2M | $0.11 | — |
| FY 2025 | $33.5M | 99.4% | $-51.8M | $-53.0M | $-1.11 | — |
| Q3 2025 | $861.0K | 94.3% | $-20.3M | $-20.8M | $-0.40 | — |
| Q2 2025 | $836.0K | 94.5% | $-19.3M | $-19.4M | $-0.50 | — |
| Q1 2025 | $868.0K | 94.9% | $-18.9M | $-18.8M | $-0.49 | — |
| Q4 2024 | $253.0K | 77.1% | $-16.7M | $-16.2M | $-0.42 | — |
| FY 2024 | $2.6M | 92.3% | $-64.3M | $-61.0M | $-1.66 | — |
| Q3 2024 | $987.0K | 93.1% | $-16.3M | $-15.4M | $-0.41 | — |
| Q2 2024 | $778.0K | 94.3% | $-16.9M | $-16.0M | $-0.45 | — |
| Q1 2024 | $620.0K | 82.6% | $-14.4M | $-13.5M | $-0.38 | — |
| Q4 2023 | $262.0K | 68.3% | $-12.5M | $-12.8M | $-0.36 | — |
| FY 2023 | $2.8M | 93.3% | $-51.5M | $-49.1M | $-1.48 | — |